UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice

Nucleic acids research, 2014-07, Vol.42 (13), p.8796-8807

2014

Volltextzugriff (PDF)

Comprehensive Structure–Activity Relationship of Triantennary N‑Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes

Journal of medicinal chemistry, 2016-03, Vol.59 (6), p.2718-2733

2016

Volltextzugriff (PDF)

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice

Hepatology (Baltimore, Md.), 2005-08, Vol.42 (2), p.362-371

2005

Volltextzugriff (PDF)

Silencing of STE20‐type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet‐induced nonalcoholic fatty liver disease

The FASEB journal, 2021-05, Vol.35 (5), p.e21567-n/a

2021

Volltextzugriff (PDF)

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

Cell metabolism, 2006-02, Vol.3 (2), p.87-98

2006

Volltextzugriff (PDF)

Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice

Molecular therapy, 2022-07, Vol.30 (7), p.2491-2504

2022

Volltextzugriff (PDF)

Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice

The Journal of clinical investigation, 2014-01, Vol.124 (1), p.251-261

2014

Volltextzugriff (PDF)

Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice

JCI insight, 2019-06, Vol.4 (12)

2019

Volltextzugriff (PDF)

Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease

Cellular and molecular gastroenterology and hepatology, 2019-01, Vol.7 (3), p.597-618

2019

Volltextzugriff (PDF)

Specific Reduction of Hepatic Glucose 6-Phosphate Transporter-1 Ameliorates Diabetes while Avoiding Complications of Glycogen Storage Disease

The Journal of biological chemistry, 2007-06, Vol.282 (26), p.19113-19121

2007

Volltextzugriff (PDF)

Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice

Hepatology communications, 2018-01, Vol.2 (1), p.69-83

2018

Volltextzugriff (PDF)

Inhibition of Protein Tyrosine Phosphatase-1B with Antisense Oligonucleotides Improves Insulin Sensitivity and Increases Adiponectin Concentrations in Monkeys

Endocrinology (Philadelphia), 2009-04, Vol.150 (4), p.1670-1679

2009

Volltextzugriff (PDF)

Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice

American journal of physiology: endocrinology and metabolism, 2008-08, Vol.295 (2), p.E436-E445

2008

Volltextzugriff (PDF)

593 Antisense Oligonucleotide Reduction of Mutant Alpha-1 Antitrypsin Protein for the Treatment of Alpha-1 Antitrypsin Liver Disease

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.S-919-S-919

2012

Volltextzugriff (PDF)

Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression

American journal of physiology: endocrinology and metabolism, 2008-03, Vol.294 (3), p.E530-E539

2008

Volltextzugriff (PDF)

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice

Hepatology (Baltimore, Md.), 2005-08, Vol.42 (2), p.362-371

2005

Volltextzugriff (PDF)

Targeted Delivery of Stk25 Antisense Oligonucleotides toHepatocytes Protects Mice Against Nonalcoholic FattyLiverDisease

Cellular and molecular gastroenterology and hepatology, 2019, Vol.7 (3), p.597

2019

Volltextzugriff (PDF)

Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver DiseaseSummary

Cellular and molecular gastroenterology and hepatology, 2019-01, Vol.7 (3), p.597-618

2019

Volltextzugriff (PDF)

Reduction of JNKI expression with antisense oligonucleotide improves adiposity in obese mice

American journal of physiology: endocrinology and metabolism, 2008-08, Vol.295 (2), p.E436

2008

Volltextzugriff (PDF)

Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice

American journal of physiology: endocrinology and metabolism, 2008, Vol.58 (2)

2008

Volltextzugriff (PDF)

Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression

American journal of physiology: endocrinology and metabolism, 2008, Vol.57 (3)

2008

Volltextzugriff (PDF)

Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease

Rare diseases (Austin, Tex.), 2014, Vol.2 (1), p.e28511-e28511

2014

Volltextzugriff (PDF)

Additive Glucose Lowering Effects of a Novel PTP-1B Antisense Oligonucleotide (ISIS 113715) with Rosiglitazone and Metformin in ZDF Rats

Diabetes (New York, N.Y.), 2005-06, Vol.54, p.A373

2005

Volltextzugriff (PDF)

ORALS: MANIPULATING MOUSE METABOLISM

Diabetes (New York, N.Y.), 2004-06, Vol.53, p.A70

2004

Volltextzugriff (PDF)

Antisense Reduction of Mutant COMP Reduces Growth Plate Chondrocyte Pathology

Molecular therapy, 2017-03, Vol.25 (3), p.705-714

2017

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice

Comprehensive Structure–Activity Relationship of Triantennary N‑Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice

Silencing of STE20‐type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet‐induced nonalcoholic fatty liver disease

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice

Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice

Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice

Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease

Specific Reduction of Hepatic Glucose 6-Phosphate Transporter-1 Ameliorates Diabetes while Avoiding Complications of Glycogen Storage Disease

Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice

Inhibition of Protein Tyrosine Phosphatase-1B with Antisense Oligonucleotides Improves Insulin Sensitivity and Increases Adiponectin Concentrations in Monkeys

Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice

593 Antisense Oligonucleotide Reduction of Mutant Alpha-1 Antitrypsin Protein for the Treatment of Alpha-1 Antitrypsin Liver Disease

Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice

Targeted Delivery of Stk25 Antisense Oligonucleotides toHepatocytes Protects Mice Against Nonalcoholic FattyLiverDisease

Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver DiseaseSummary

Reduction of JNKI expression with antisense oligonucleotide improves adiposity in obese mice

Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice

Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression

Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease

Additive Glucose Lowering Effects of a Novel PTP-1B Antisense Oligonucleotide (ISIS 113715) with Rosiglitazone and Metformin in ZDF Rats

ORALS: MANIPULATING MOUSE METABOLISM

Antisense Reduction of Mutant COMP Reduces Growth Plate Chondrocyte Pathology

Suchergebnisse filtern